Prosecution Insights
Last updated: October 24, 2026
Application No. 18/632,347

ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES

Non-Final OA §112
Filed
Apr 11, 2024
Priority
May 05, 2023 — provisional 63/500,273
Examiner
KIFLE, BRUCK
Art Unit
Tech Center
Assignee
UNIVERSAL DISPLAY Corporation
OA Round
1 (Non-Final)
79%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
95%
With Interview

Examiner Intelligence

Grants 79% — above average
79%
Career Allowance Rate
1381 granted / 1742 resolved
+19.3% vs TC avg
Strong +16% interview lift
Without
With
+15.8%
Interview Lift
resolved cases with interview
Fast prosecutor
1y 10m
Avg Prosecution
45 currently pending
Career history
1788
Total Applications
across all art units

Statute-Specific Performance

§101
5.9%
-34.1% vs TC avg
§103
12.7%
-27.3% vs TC avg
§102
12.2%
-27.8% vs TC avg
§112
53.9%
+13.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1742 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of the compound in pages 117 and 118 in the reply filed on August 19, 2026 is acknowledged. The elected compound is named “Emitter 1” in the specification, Table 1, page 118. Both compounds of Table 1, “Emitter 1” and “Emitter 2” were not found in the prior art and are allowable. Improper Markush Rejection Claims 1-20 are rejected under a judicially created doctrine as being drawn to an improper Markush group, that is, the claims lack unity of invention. The variables X1-X10, Y1-Y2, K1-K4, A1-A4 and L1-L4 are defined in such a way that they keep changing the core of the compound that determines the classification. By changing these values, several patentably distinct and independent compounds are claimed. In order to have unity of invention the compounds must have “a community of chemical or physical characteristics” which justify their inclusion in a common group, and that such inclusion is not repugnant to principles of scientific classification” In re JONES (CCPA) 74 USPQ 149 (see footnote 2). The structural Formula (I) does not have a significant structural feature that is shared by all of its alternatives which is inventive. The structure has only a single N in a ring as common. This feature is not inventive. Compounds embraced by Formula (I) are so diverse in nature that a prior art anticipating a claim with respect to one member under 35 USC 102 would not render obvious the same claim under 35 USC 103. This is evidentiary of patentably distinct and independent inventions. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 13-15, 18 and 20 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. i) In claim 13, the definitions of LA’ and Ly are defined as “selected from the group consisting of structures shown below (LIST 1) and LIST 2” and selected from the group consisting of structures shown below (LIST 3) and LIST 4,” respectively. There is, however, no structure for these groups or any other definition. Appropriate correction is required. Also, the phrase “from the General substituents as defined herein; and any two substituents can be fused or joined to form a ring” is unclear. Are these definitions narrowing any previous limitation? If not, the phrase is confusing and superfluous because the definitions of variables carry over into dependent claims unless there is a clear further narrowing. See also claims 14 and 15. Similar language is present in claim 18. ii) In claim 20 it is not known what else is present in the formulation. A formulation necessarily requires the presence of additional ingredients to distinguish it from the compound. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRUCK KIFLE whose telephone number is (571)272-0668. The examiner can normally be reached 8 AM - 6 PM, M-F. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey H. Murray can be reached at 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. October 5, 2026 /BRUCK KIFLE/Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Apr 11, 2024
Application Filed
Oct 07, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12766146
Salts and Solid Form of a BTK Inhibitor
4y 5m to grant Granted Oct 20, 2026
Patent 12767637
MITOCHONDRIAL TARGETING COMPOUNDS FOR THE TREATMENT OF ASSOCIATED DISEASES
3y 11m to grant Granted Oct 20, 2026
Patent 12765555
METHOD FOR CONTROLLING WEEDS
3y 3m to grant Granted Oct 20, 2026
Patent 12766152
GEL COMPOSITION FOR PREVENTION OR TREATMENT OF ATOPIC DERMATITIS
2y 7m to grant Granted Oct 20, 2026
Patent 12760005
BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS
3y 8m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
79%
Grant Probability
95%
With Interview (+15.8%)
1y 10m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1742 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month